MannKind Corporation
Every calculator, already run for MNKD
Open the full toolkit →You have the numbers on MNKD. Get the argument.
A written report on which of these readings actually decide the outcome for MannKind Corporation, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
8 analysts covering MNKDAnalyst Price Target Disagreement for MannKind Corporation
Wall Street's bull case implies +250% from the current price; the bear case implies +28%. A 222% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for MNKD
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous…
MNKD — frequently asked
Is MNKD a buy right now?
Wall Street's consensus rating on MannKind Corporation is Strong Buy across 8 analysts, with a mean price target of $7.97 (+115% vs. the current $3.71). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is MNKD overvalued?
MNKD trades at — trailing earnings, against a DCF fair value of $3 per share. The current price implies 9% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is MNKD's next earnings date?
MannKind Corporation is next scheduled to report earnings around Nov 4, 2026. A full MNKD research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for MannKind Corporation?
Analysts covering MannKind Corporation (MNKD) range from a bear-case target of $4.75 to a bull-case high of $13.00, with a mean consensus target of $7.97 across 8 analysts. The spread of $8.25 (222% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare MannKind Corporation against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For MannKind Corporation
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full MNKD research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on MannKind Corporation, in minutes. 3 free reports included with every account — no credit card required.